GEODE CAPITAL MANAGEMENT, LLC - LYELL IMMUNOPHARMA INC ownership

LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 80 filers reported holding LYELL IMMUNOPHARMA INC in Q1 2022. The put-call ratio across all filers is 0.02 and the average weighting 1.1%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of LYELL IMMUNOPHARMA INC
ValueSharesWeighting
Q3 2023$5,375,641
-49.9%
3,656,483
+8.3%
0.00%0.0%
Q2 2023$10,735,133
+42.7%
3,375,828
+5.9%
0.00%0.0%
Q1 2023$7,524,706
+70954.8%
3,188,435
+4.5%
0.00%0.0%
Q4 2022$10,590
-100.0%
3,052,005
+3.4%
0.00%
-66.7%
Q3 2022$21,628,000
+76.8%
2,950,650
+57.3%
0.00%
+50.0%
Q2 2022$12,232,000
+66.6%
1,876,087
+29.0%
0.00%
+100.0%
Q1 2022$7,343,000
+69.8%
1,454,233
+160.3%
0.00%0.0%
Q4 2021$4,324,000
-45.1%
558,726
+5.0%
0.00%0.0%
Q3 2021$7,871,000
+177.9%
531,885
+204.9%
0.00%
Q2 2021$2,832,000174,4200.00%
Other shareholders
LYELL IMMUNOPHARMA INC shareholders Q1 2022
NameSharesValueWeighting ↓
MWG Management Ltd. 20,162,332$131,458,00059.13%
Apoletto Ltd 15,093,969$98,413,00027.22%
Foresite Capital Management IV, LLC 13,282,181$86,600,00023.32%
MIC Capital Management UK LLP 3,060,569$19,955,0003.90%
Alphabet Inc. 5,865,125$38,241,0002.08%
HSG Holding Ltd 3,045,997$19,860,0001.83%
Board of Trustees of The Leland Stanford Junior University 1,647,882$10,744,0000.72%
SG3 Management, LLC 600,000$3,912,0000.46%
KETTLE HILL CAPITAL MANAGEMENT, LLC 157,700$1,028,0000.26%
Artal Group S.A. 700,000$4,564,0000.24%
View complete list of LYELL IMMUNOPHARMA INC shareholders